Skip to main content
CNCCentene CorporationSell5.0·$61.39-3.17%
Open full analysis

Centene Corporation (CNC) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Healthcare Plans

Sell if holding. Engine safety override at $61.39: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality.

Centene is the largest U.S. managed care company focused on underserved populations, with $194.8 billion in 2025 revenues and 27.6 million members. It is the largest Medicaid insurer (12.5M members in 30 states), largest ACA Marketplace carrier (5.5M members), and largest... Read more

$61.39+6.2% A.UpsideScore 5.0/10#8 of 11 Healthcare Plans
QualityF-score6 / 9FCF yield21.87%
Stop $57.09Target $65.22(resistance)A.R:R -1.2:1
Analyst target$61.35-0.1%17 analysts
$65.22our TP
$61.39price
$61.35mean
$40
$80

Sell if holding. Engine safety override at $61.39: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.

Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About Centene Corporation

About Centene Corporation

Centene's government-focused health plans generated $194.8 billion in total revenues in 2025 across 27.6 million members, with Medicaid at 57% of external revenues, Commercial at 21%, and Medicare at 19%. The company served 12.5 million Medicaid members across 30 states, 5.5 million Marketplace members in 29 states under the Ambetter Health brand, and 8.1 million Part D PDP members as of December 31, 2025, making it the nation's largest Medicaid, Marketplace, and stand-alone PDP insurer.

Centene earns revenue primarily through capitation rates set by government payors — CMS for Medicare Advantage and PDP plans, and state actuarial agencies for Medicaid. Medicare Advantage premiums vary by county, demographics, and risk scores under retroactive risk-adjustment models; roughly 60% of the company's Medicare Advantage membership was associated with contracts rated 3.5 stars or better as of December 2025. The Medicaid segment spans Medicaid Expansion, TANF, ABD, CHIP, LTSS, and foster care populations; state actuarial rate-setting typically lags actual medical cost trends, creating timing risk on earnings. The Inflation Reduction Act's Part D changes — including a $2,100 annual out-of-pocket cap for 2026 and a shift in insurer catastrophic-phase cost-sharing — substantially increased PDP financial risk, prompting Centene to elect into CMS's Part D Premium Stabilization Demonstration program. Commercial Marketplace coverage is distributed under the Ambetter Health brand across 29 states, and the Other segment includes specialty pharmacy, behavioral health, and vision and dental services.

Show full overview

The One Big Beautiful Bill Act, passed in July 2025, introduces work requirements and more frequent eligibility redeterminations for Medicaid Expansion populations beginning in 2027, plus adjustments to provider taxes beginning in 2028 — changes that may reduce membership and increase morbidity in remaining enrolled populations depending on state implementation timelines. New York intends to terminate its Essentials Plan-5 by July 1, 2026, directly reducing the company's Commercial membership. Separately, CMS announced in 2025 an expanded scope and accelerated timing for risk-adjustment data validation audits, exposing the company to potentially significant retroactive premium refunds depending on audit outcomes.

See also: Healthcare · Healthcare Plans

From Centene Corporation's most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-17

Recent Developments — Centene Corporation

Generated 2026-06-17T09:36:57Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Jul 28, 202642d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Medicaid (57.0%)
Target reached (-10.1% upside)
Quality below floor (2.3 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)14.2
Mkt Cap$31.3B
EV/EBITDA8.3
Profit Mgn-3.6%
ROE-26.0%
Rev Growth5.1%
Beta1.09
DividendNone
Rating analysts26

Quality Signals

Piotroski F6/9

Options Flow

P/C0.75neutral
IV57%elevated
Max Pain$90+46.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductMedicaid57%
    10-K Item 1: 'our Medicaid, Commercial, Medicare and Other segments accounted for 57%, 21%, 19% and 3%, respectively, of our total external revenues'
  • MEDIUMGeographicFlorida and New York Medicaid contracts
    10-K Item 1: 'Our Medicaid contracts with the states of Florida and New York accounted for approximately 10% or more of our consolidated Medicaid premium revenues individually'

Material Events(8-K, last 90d)

  • 2026-03-24Item 5.02LOW
    Theodore Pienkos appointed Corporate Controller and Chief Accounting Officer effective March 18, 2026. Previously Deputy Corporate Controller since August 2024. Base salary $440K, 60% target bonus. No predecessor departure cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Unprofitable operations — net margin -3.6%. Quality floor flags this regardless of sector context.static

Roe
0.0
Gross Margin
0.0
Net Margin
0.0
Roa
0.8
Operating Margin
2.0
Current Ratio
4.4
Moat
4.4
Piotroski F
6.7
No competitive moatQuality concerns
GatesMomentum 4.1<4.5A.R:R -1.2=NEGATIVEExecutive change: officer departure/appointmentInsider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 42d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
56 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $56.74Resistance $66.55

Price Targets

$57
$65
A.Upside+6.2%
A.R:R-1.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-10.1% upside)
! Quality below floor (2.3 < 4.0)
! momentum at 4.1 (below the engine's 4.5 threshold)

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-28 (42d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CNC stock a buy right now?

Sell if holding. Engine safety override at $61.39: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $57.09. Score 5.0/10, moderate confidence.

What is the CNC stock price target?

Take-profit target: $65.22 (+6.2% upside). Prior stop was $57.09. Stop-loss: $57.09.

What are the risks of investing in CNC?

Concentration risk — Product: Medicaid (57.0%); Target reached (-10.1% upside); Quality below floor (2.3 < 4.0).

Is CNC overvalued or undervalued?

Centene Corporation trades at a P/E of N/A (forward 14.2). TrendMatrix value score: 6.9/10. Verdict: Sell.

What do analysts say about CNC?

26 analysts cover CNC with a consensus score of 3.5/5. Average price target: $61.

What does Centene Corporation do?Centene is the largest U.S. managed care company focused on underserved populations, with $194.8 billion in 2025...

Centene is the largest U.S. managed care company focused on underserved populations, with $194.8 billion in 2025 revenues and 27.6 million members. It is the largest Medicaid insurer (12.5M members in 30 states), largest ACA Marketplace carrier (5.5M members), and largest stand-alone PDP provider (8.1M members).

Related stocks: ALHC (Alignment Healthcare, Inc.) · OSCR (Oscar Health, Inc.) · CI (The Cigna Group) · CVS (CVS Health Corporation) · HUM (Humana Inc.)
Home Stocks CNC

Latest news

Latest News

Benzinga16h agoCONCERN
Benzinga2d agoCONCERN
Benzinga9d agoAnalyst
Benzinga9d agoAnalyst
Benzinga13d agoAnalyst
Benzinga13d agoAnalyst
Benzinga16d agoAnalyst
Benzinga26d ago
Benzinga26d ago
Benzinga26d agoAnalyst
Benzinga28d agoAnalyst
Benzinga28d agoAnalyst
Benzinga36d ago
Benzinga44d agoAnalyst
Benzinga45d ago
Benzinga47d ago
Benzinga47d agoAnalyst
Benzinga48d ago
Benzinga48d agoAnalyst
Benzinga48d ago
Loading more...